NCT05241132 is a Phase 2 clinical trial of Tislelizumab plus chemotherapy in Cancer of Unknown Primary, sponsored by Wei Xu.

Who is sponsoring NCT05241132?

NCT05241132 is sponsored by Wei Xu.

What drugs are being tested in NCT05241132?

Interventions in NCT05241132: Tislelizumab plus chemotherapy.

What condition does NCT05241132 study?

NCT05241132 studies Cancer of Unknown Primary, Bone Cancer Metastatic, Tislelizumab, Gene Mutation-Related Cancer, Immune Evasion, Tumor, Chemotherapy Effect.

Is NCT05241132 still recruiting?

NCT05241132 is currently status unknown. Last updated 15 February 2022.

Last reviewed 2022-02-15 · How we verify

NCT05241132

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Tislelizumab Combined With Chemotherapy in the Treatment of Bone Metastases of Unknown Primary

Status unknown Phase 2 Last updated 15 February 2022

What this trial tests

Phase 2 trial testing Tislelizumab plus chemotherapy in Cancer of Unknown Primary in 27 participants. Status unknown.

Timeline

12 November 2021

Primary endpoint
30 June 2023

31 October 2024

Quick facts

Lead sponsor	Wei Xu
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	27
Start date	12 November 2021
Primary completion	30 June 2023
Estimated completion	31 October 2024
Sites	1 location across China

Drugs / interventions tested

Tislelizumab plus chemotherapy — full drug profile →

Conditions studied

Cancer of Unknown Primary — all drugs for Cancer of Unknown Primary →
Bone Cancer Metastatic — all drugs for Bone Cancer Metastatic →
Tislelizumab — all drugs for Tislelizumab →
Gene Mutation-Related Cancer — all drugs for Gene Mutation-Related Cancer →

Sponsor

Wei Xu — full company profile →

Who can join

18 and older, any sex, with Cancer of Unknown Primary or Bone Cancer Metastatic. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Through scientific and rigorous design, implementation, follow-up and statistics, the sponsor aims to explore the clinical efficacy and safety of Tislelizumab combined with chemotherapy (platinum + paclitaxel) in the treatment of patients with bone metastases cancer with unknown primary, and provide a better treatment plan for these patients. 1. Primary outcome: Objective response rate (ORR) 2. Secondary outcomes: disease control rate (DCR), duration of remission (DOR), progression-free disease (PFS), overall survival (OS), median PFS, median OS, stratification based on clinical features and PD-L1 expression, adverse reactions (AEs), and quality of life.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Decoding the Impact of Tumor Microenvironment in Osteosarcoma Progression and Metastasis.
Nirala BK, Yamamichi T, Petrescu DI, Shafin TN, et al · · 2023 · cited 36× · PMID 37894474 · DOI 10.3390/cancers15205108
Deciphering the Signaling Mechanisms of Osteosarcoma Tumorigenesis.
Nirala BK, Yamamichi T, Yustein JT. · · 2023 · cited 32× · PMID 37511127 · DOI 10.3390/ijms241411367
Promise and Challenges of T Cell Immunotherapy for Osteosarcoma.
Park JA, Cheung NV. · · 2023 · cited 26× · PMID 37569894 · DOI 10.3390/ijms241512520

Verify or expand the search:

Other recruiting trials for Cancer of Unknown Primary

Currently open trials in the same condition.

NCT06695494 — Enabling Genomic Testing in Cancer of Unknown Primary · recruiting

Other Wei Xu trials

Trials by the same sponsor.

NCT07385989 — Golidocitinib Combined With P-GemOx Plus PD-1 Inhibitor Versus P-GemOx Plus PD-1 Inhibitor in First-Line Newly Diagnosed · Phase 2 · not yet recruiting
NCT05173467 — Robot-assisted Invasion-controlled Surgery Versus Traditional-open Surgery Against Metastatic Spinal Tumor · NA · unknown
NCT03892252 — Characteristics of Gut Microbiota in Patients With Colon Cancer of Different Traditional Chinese Medicine Syndromes · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05241132 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Wei Xu
Last refreshed: 15 February 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05241132.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing